Combined stem cell and hormone replacement therapies for treatment of premature ovarian failure

Human umbilical cord mesenchymal stem cells (hUC-MSCs) and human cord blood mononuclear cells (hCB-MNCs) have been shown to modulate the immune response and enhance angiogenesis, suggesting a novel and promising therapeutic strategy for premature ovarian failure (POF). This study aims to assess the safety and efficacy of hUCMSC and hCBMNC transplantation combined with hormone replacement therapy (HRT) in patients with POF. Participants will be followed for an expected average of 48 weeks.